Indoco Remedies Ltd

- No explicit mention of any current or planned fundraising through debt or equity in the provided transcript. - The company focused on dealing with remediation, operational challenges, and cost control measures. - Capex for refurbishment and new capacity was funded through internal resources; INR400+ crores spent in the past 2 years. - No guidance or statement was given regarding raising fresh equity or debt funding in the near future. - The management emphasized operational efficiency, digitization, and ramp-up post regulatory challenges rather than external fundraising.

- Indoco Remedies has undertaken significant capex of around INR 400 crores in the past 2 years, mainly for refurbishment and capacity expansion. - Key investments include: - Setting up a new unit at Auric for manufacturing cosmetic toothpaste (OTC toothpaste). - Capacity increase for API production beyond the old site at Patalganga. - Upgrading equipment to improve efficiency at the solid oral manufacturing site. - In the current year, about INR 200 crores has been incurred, covering new machines, upgrades, refurbishment, and some advances. - Equipment upgrades are aligned with digital initiatives to enable data collection and AI/ML applications for predictive quality and efficiency improvements. - Refurbishments at the sterile plant involve repairs and maintenance rather than complete line replacements. - Future capex is planned but details on quantum or timelines are under evaluation, especially linked to remediation and capacity ramp-up.

- The order book for international formulations business to Europe and US stands at about INR180 crores, indicating expected sales recovery. - Europe business is expected to drive growth with an anticipated margin of close to 15% starting FY '26. - US business recovery is delayed due to FDA remediation; scale-up expected once compliance issues resolve. - Domestic business shows steady growth with top brands like Cyclopam growing over 20% in prescriptions. - New product launches and strategic partnerships (e.g., with Clarity Pharma UK for 18 SKUs over 18 months) support revenue growth. - Semi-regulated markets expected to perform better with efforts to smoothen distributor order patterns. - Overall, sales growth expected to return with normalization post remediation and capacity ramp-up, likely from FY '26 onwards.

- Short-term (next two quarters) earnings are expected to remain impacted due to US FDA warning letter issues and supply constraints from the sterile plant. - EBITDA margins outlook: - This year averaging ~10.5-11% due to challenges; previous year was ~13%. - Recovery to ~13% EBITDA margins possible by Q3 FY '26 with gradual ramp-up. - The India domestic business and international non-US geographies are expected to recover and grow steadily from FY '26 onwards. - International formulations order book stands strong at INR180 crores, indicating demand. - Cost control measures and master manufacturing plan aim to improve operational efficiency and reduce fixed costs over time. - Capex investments and digital/SAP improvements are expected to enhance productivity and margins in the medium term. - Chronic portfolio contribution may inch up but with ongoing aggressive growth in other segments. - No specific earnings per share (EPS) guidance disclosed currently.

- The current order book for the international formulations business to Europe and the US stands at approximately INR 180 crores. - This order book reflects the demand side strength despite supply-side challenges. - The company has faced a significant sales drop in the regulated markets due to remediation and supply disruptions but holds this order backlog as a positive indicator. - There is an expectation of recovery in supply and a return to earlier performance levels in markets outside the US starting from FY '26 onwards. - The supply challenges have led to a temporary loss of revenue, with an example of INR 90-100 crores of sales lost in one quarter alone due to these delays. - Overall, the order book suggests healthy demand and potential for ramp-up once compliance and production issues are resolved.